Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials

Guidelines recommend the use of potent P2Y12 inhibitors over clopidogrel for the reduction of ischaemic events in patients with acute coronary syndrome (ACS). However, this comes at the expense of increased bleeding. A guided selection of P2Y12 inhibiting therapy has the potential to overcome this l...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	European heart journal Ročník 43; číslo 10; s. 959
Hlavní autori:	Galli, Mattia, Benenati, Stefano, Franchi, Francesco, Rollini, Fabiana, Capodanno, Davide, Biondi-Zoccai, Giuseppe, Vescovo, Giovanni Maria, Cavallari, Larisa H, Bikdeli, Behnood, Ten Berg, Jurrien, Mehran, Roxana, Gibson, Charles Michael, Crea, Filippo, Pereira, Naveen L, Sibbing, Dirk, Angiolillo, Dominick J
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	England 07.03.2022
Predmet:	Acute Coronary Syndrome Humans Percutaneous Coronary Intervention Platelet Aggregation Inhibitors - adverse effects Platelet Aggregation Inhibitors - therapeutic use Prasugrel Hydrochloride - adverse effects Prasugrel Hydrochloride - therapeutic use Purinergic P2Y Receptor Antagonists - adverse effects Purinergic P2Y Receptor Antagonists - therapeutic use Randomized Controlled Trials as Topic Ticagrelor - adverse effects Ticagrelor - therapeutic use Treatment Outcome Antiplatelet therapy Prasugrel P2Y12 inhibitors Platelet function Clopidogrel Genetic testing Acute coronary syndrome Ticagrelor
ISSN:	1522-9645, 1522-9645
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!